Movement Alert|Zoetis Falls 4.04% in Regular Trading, USDA approval for three-disease chicken vaccine failed to lift shares

Market Focus
11/19

On November 19, Zoetis fell 4.04% in Regular Trading, trading at $82.2101 per share with turnover of $28.1379 million.

The clearest recent catalyst was the company’s announcement that the US Department of Agriculture licensed Poulvac Procerta HVT-ND-ILT, a vector vaccine for chickens designed to protect against Marek's disease, Newcastle disease, and infectious laryngotracheitis. However, the approval did not improve market sentiment, with the stock also indicated lower earlier in the session.

Background factors may have limited the positive read-through. Zoetis reported September-quarter revenue of $2.39 billion, down 1% year over year, although adjusted EPS of $1.75 topped expectations and full-year revenue guidance was raised to $9.22 billion to $9.32 billion. Even with the product approval, investors appear to remain cautious on the durability of growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10